AlphAIAlphAI — Financial news for AI agents
stocktitan.netOCT 121 min read$ORGO

A 5 p.m. call will cover Organogenesis' quarterly results Nov. 5

Organogenesis Holdings Inc. (ORGO) will release its Q3 2026 financial results after market close on Nov. 5. A conference call is scheduled for 5 p.m. ET to discuss results and provide a corporate update. The webcast will be available live and archived on the company's website.

Original reporting
stocktitan.net
Published Oct 12, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ORGO
Neutral
medium confidence
Mentioned
$ORGO
Relevance
5/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$ORGONeutralLow
01

Why it matters

The call announcement sets the timeline for investors to prepare for the earnings release; no immediate market move is expected.

02

Market read

Provides a scheduling update for the upcoming earnings release; relevance is limited to traders focused on biotech earnings.

03

What to watch

Potential guidance changes or surprise clinical trial updates that could move the stock after the call.

Relevance 5/10Novelty 4/10Timing: pre‑market on Nov 5

Background

Organogenesis is a Nasdaq‑listed regenerative‑medicine firm that regularly reports quarterly results.

Company-level read

Ticker impact

$ORGONeutralMedium confidence
Context

Organogenesis announced its Q3 FY2026 earnings will be released after market close on Nov 5, with a 5 p.m. call.

Expected impact

no immediate price pressure; market may price in earnings expectations later on Nov 5

Evidence & confidence

Without numbers, traders cannot act now; impact will depend on the actual results.

Market effects

Sector

Regenerative‑medicine sector may see heightened attention ahead of the earnings release.

Regional

Limited to U.S. investors tracking biotech earnings calendar.

Global

Minimal; the news is company‑specific.

Counterpoint

What could challenge this read

If the market has already priced in strong growth, the earnings could disappoint, prompting a sell‑off.

Key entities

  • company
    Organogenesis Holdings Inc.

    Regenerative‑medicine company (Nasdaq: ORGO).

Read at source← All news

Related articles

AUG 15
$ORGOMed

Organogenesis (ORGO) Q2 2026 Earnings Call Transcript

Organogenesis (ORGO) reported Q2 2026 revenue down 58% year over year, driven by a 61% drop in Advanced Wound Care sales. Net product revenue rose 18% quarter over quarter. The company cited CMS coverage changes as slowing recovery, announced a June restructuring with 138 job cuts and about $18M annualized cost savings, and updated 2026 revenue guidance. It also cited DFU and venous ulcer study results and FDA acceptance of Amnuvx BLA with a PDUFA date of Apr 24, 2027.

yahoo.com10 min
AUG 6
$ORGOMed

Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results

Organogenesis Holdings Inc. (ORGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results CANTON, Mass., (August 6, 2026) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing

SEC EDGAR 8-K6 min
JUL 7
$ORGOMedAI 8/10

Organogenesis Secures FDA Review For ReNu In Knee Osteoarthritis

Organogenesis Holdings (ORGO) said the FDA accepted its BLA for ReNu, a cryopreserved amniotic suspension allograft for pain in symptomatic knee osteoarthritis. The company cited 3 randomized trials with 1,300+ patients and prior RMAT designation (2021). FDA set a PDUFA action date of April 24, 2027; “Amnuvx” is conditionally accepted as the proprietary name.

rttnews.com3 min
JUL 6
$ORGOMed

Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis

Organogenesis Holdings (Nasdaq: ORGO) said the FDA accepted for review its Biologics License Application for ReNu, a cryopreserved amniotic suspension allograft for symptomatic knee osteoarthritis pain. The FDA set a PDUFA target action date of April 24, 2027. The company noted ReNu has RMAT designation and was studied in three RCTs (>1,300 patients).

manilatimes.net3 min